Hepion Pharmaceuticals, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 48.93 million compared to USD 42.2 million a year ago. Basic loss per share from continuing operations was USD 12.32 compared to USD 11.9 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.02 USD | -1.92% | -3.77% | -68.52% |
May. 21 | Hepion Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Apr. 22 | Sector Update: Health Care Stocks Increase Late Afternoon | MT |
1st Jan change | Capi. | |
---|---|---|
-68.52% | 5.69M | |
+15.58% | 122B | |
+16.60% | 113B | |
+17.55% | 26.22B | |
-24.33% | 19.01B | |
-19.14% | 15.71B | |
-17.95% | 15.22B | |
-46.81% | 14.72B | |
+58.78% | 14.58B | |
+4.91% | 13.84B |
- Stock Market
- Equities
- HEPA Stock
- News Hepion Pharmaceuticals, Inc.
- Hepion Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023